LNS8801 with or without pembrolizumab for advanced melanoma
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new drug called LNS8801, alone or with pembrolizumab, for people with advanced melanoma that has stopped responding to prior treatments, especially anti-PD-1 therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced melanoma that cannot be removed by surgery or has spread to other parts of your body.
- Your tumor has two working copies of a specific gene called GPER.
- You have tried and your disease has worsened on a treatment that works on the PD-1 pathway (like Keytruda or Opdivo).
- You are willing and able to take at least one of the standard treatments your doctor chooses.
- You can swallow tablets.
- Your overall health is good enough for daily activities (ECOG score of 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (LTX-315 and pembrolizumab) given before surgery to shrink melanoma that is stage III or IV (M1a) and can be removed. The goal is to see if this approach works better than surgery alone.
This trial tests whether giving immunotherapy before surgery and possibly skipping some after may help people with advanced but removable melanoma. It aims to see if this approach can reduce the chance of the cancer coming back.
This trial studies whether adding lifileucel (a patient-specific immune-cell treatment) to pembrolizumab works better than pembrolizumab alone. It’s for people with untreated advanced melanoma that cannot be removed by surgery.
This Phase 1 trial studies a new experimental immunotherapy (MBS8) for people with advanced solid tumors, focusing first on safety and early signs of benefit. Depending on your cancer type and past treatments, you may receive MBS8 alone or combined with pembrolizumab.
This trial tests a combination of daily low-dose cyclophosphamide (a chemotherapy pill) and pembrolizumab (an immunotherapy) in people with advanced melanoma that has stopped responding to prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
This Phase 1/2 study tests the safety and early signs of benefit from CJRB-101 when combined with pembrolizumab (Keytruda) in people with advanced or metastatic lung, head and neck, or melanoma cancer. It may help some participants, but the main goal is to see how safe the combination is and whether it can control cancer.
Hear when a new Melanoma (Skin Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.